BRIEF-CRISM' Therapeutics Corp Says Phase 2 Clinical Trial For Irinotecan-ChemoSeed To Begin In Q1 2026

Reuters2025-10-30

BRIEF-CRISM' <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Corp Says Phase 2 Clinical Trial For Irinotecan-ChemoSeed To Begin In Q1 2026

Oct 30 (Reuters) - CRISM' Therapeutics Corp CRTX.L:

CRISM THERAPEUTICS - US ORPHAN DRUG DESIGNATION APPLICATION
CRISM' THERAPEUTICS CORP - PHASE 2 CLINICAL TRIAL FOR IRINOTECAN-CHEMOSEED TO BEGIN IN Q1 2026
CRISM' THERAPEUTICS CORP - CRISM SUBMITS APPLICATION FOR ORPHAN DRUG DESIGNATION TO FDA

Source text: ID:nRSd4097Fa

Further company coverage: CRTX.L

((Reuters.Briefs@thomsonreuters.com;;))

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2579195764?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-30 15:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2579195764","market":"fut","top_or_hot":-1,"title":"BRIEF-CRISM' Therapeutics Corp Says Phase 2 Clinical Trial For Irinotecan-ChemoSeed To Begin In Q1 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-CRISM' <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Corp Says Phase 2 Clinical Trial For Irinotecan-ChemoSeed To Begin In Q1 2026</title></head><body><p><span>Oct 30 (Reuters)</span><span> - </span>CRISM' Therapeutics Corp <span>CRTX.L</span>:</p><ul><li><p>CRISM THERAPEUTICS  - US ORPHAN DRUG DESIGNATION APPLICATION</p></li><li><p>CRISM' THERAPEUTICS CORP - PHASE 2 CLINICAL TRIAL FOR IRINOTECAN-CHEMOSEED TO BEGIN IN Q1 2026</p></li><li><p>CRISM' THERAPEUTICS CORP - CRISM SUBMITS APPLICATION FOR ORPHAN DRUG DESIGNATION TO FDA</p></li></ul><p>Source text: <span>ID:nRSd4097Fa</span></p><p>Further company coverage: <span>CRTX.L</span></p><p> ((Reuters.Briefs@thomsonreuters.com;;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-CRISM' Therapeutics Corp Says Phase 2 Clinical Trial For Irinotecan-ChemoSeed To Begin In Q1 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-CRISM' Therapeutics Corp Says Phase 2 Clinical Trial For Irinotecan-ChemoSeed To Begin In Q1 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-10-30 15:24</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-CRISM' <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Corp Says Phase 2 Clinical Trial For Irinotecan-ChemoSeed To Begin In Q1 2026</title></head><body><p><span>Oct 30 (Reuters)</span><span> - </span>CRISM' Therapeutics Corp <span>CRTX.L</span>:</p><ul><li><p>CRISM THERAPEUTICS  - US ORPHAN DRUG DESIGNATION APPLICATION</p></li><li><p>CRISM' THERAPEUTICS CORP - PHASE 2 CLINICAL TRIAL FOR IRINOTECAN-CHEMOSEED TO BEGIN IN Q1 2026</p></li><li><p>CRISM' THERAPEUTICS CORP - CRISM SUBMITS APPLICATION FOR ORPHAN DRUG DESIGNATION TO FDA</p></li></ul><p>Source text: <span>ID:nRSd4097Fa</span></p><p>Further company coverage: <span>CRTX.L</span></p><p> ((Reuters.Briefs@thomsonreuters.com;;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CRTX.UK","symbol_name":"CRISM THERAPEUTICS CORPORATION","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251030:nTUC4F4N3M:1","article_id":"2579195764","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2579195764","pubTimestamp":1761809059,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-CRISM' Therapeutics Corp Says Phase 2 Clinical Trial For Irinotecan-ChemoSeed To Begin In Q1 2026Oct 30 (Reuters) - CRISM' Therapeutics Corp CRTX.L:CRISM THERAPEUTICS  - US ORPHAN DRUG DESIGNATI","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CRTX.UK":"CRISM THERAPEUTICS CORPORATION","BK5083":"生物科技","BK5111":"多种金属与采矿"},"translate_title":"BRIEF-CRISM'Therapeutics Corp表示伊立替康-ChemoSeed的2期临床试验将于2026年第一季度开始","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CRTX.UK":0.9},"content_text":"BRIEF-CRISM' Therapeutics Corp Says Phase 2 Clinical Trial For Irinotecan-ChemoSeed To Begin In Q1 2026Oct 30 (Reuters) - CRISM' Therapeutics Corp CRTX.L:CRISM THERAPEUTICS  - US ORPHAN DRUG DESIGNATION APPLICATIONCRISM' THERAPEUTICS CORP - PHASE 2 CLINICAL TRIAL FOR IRINOTECAN-CHEMOSEED TO BEGIN IN Q1 2026CRISM' THERAPEUTICS CORP - CRISM SUBMITS APPLICATION FOR ORPHAN DRUG DESIGNATION TO FDASource text: ID:nRSd4097FaFurther company coverage: CRTX.L ((Reuters.Briefs@thomsonreuters.com;;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2579195764","isCrawlerRequest":true}